Key Highlights
- Reddy's Laboratories (BSE: 500124 | NSE: DRREDDY | NYSE: RDY) allotted 6,730 equity shares on June 19, 2026.
- Allotment made under Dr. Reddy's Employees Stock Option Scheme 2002 and Employees ADR Stock Option Scheme 2007.
- Exercise prices ranged from Re. 1/- to Rs. 735.80 per share across three tranches of options exercised.
- Total paid-up equity capital post-allotment: 83,46,75,800 shares of Re. 1/- each.
- ISIN of allotted shares: INE089A01031; shares rank pari passu with existing equity shares.
Company Overview
Dr. Reddy's Laboratories Limited is one of India's most globally respected pharmaceutical companies, with a presence across branded generics, biosimilars, active pharmaceutical ingredients (APIs), and proprietary products. Listed on BSE (500124), NSE (DRREDDY), NYSE (RDY), and NSE IFSC (DRREDDY), the company is headquartered at 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034, Telangana, with CIN L85195TG1984PLC004507. Dr. Reddy's serves patients in more than 66 countries and is widely regarded as a flagship of India's generic pharmaceutical industry.
ESOP Allotment: Transaction Details
Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, Dr. Reddy's Laboratories disclosed the allotment of 6,730 equity shares of face value Re. 1/- each on June 19, 2026, to eligible employees who exercised their vested stock options under two legacy ESOP schemes. The allotment was made across three tranches at different exercise prices: 2,455 shares at Re. 1/- each (nil premium); 2,000 shares at Rs. 562.80/- each (premium of Rs. 561.80 per share); and 2,275 shares at Rs. 735.80/- each (premium of Rs. 734.80 per share).
The allotted shares carry ISIN INE089A01031 with distinctive numbers ranging from 834669071 to 834675800. These shares rank pari passu in all respects with the existing equity shares of the company, including with respect to voting rights, dividend entitlement, and other shareholder benefits. There are no lock-in restrictions on the allotted shares.
ESOP Schemes: Background
The two schemes under which this allotment was made are legacy programmes that have been operational for over two decades. Dr. Reddy's Employees Stock Option Scheme, 2002 was one of the earliest ESOP programmes instituted by an Indian pharmaceutical company, and it continues to vest options to long-serving employees. The Employees ADR Stock Option Scheme, 2007 is specifically designed to grant options linked to Dr. Reddy's American Depositary Receipts (ADRs), catering to the company's international workforce.
Both schemes were originally institutionalised under the SEBI (Employee Stock Option Scheme and Employee Stock Purchase Scheme) Guidelines, 1999, and continue to comply with the updated SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The current allotment was made under Regulation 10(c) of these 2021 regulations, and the requisite details have been filed with all relevant stock exchanges.
Capital Structure Post-Allotment
Following the June 19, 2026 allotment, Dr. Reddy's total issued share capital stands at 83,46,76,800 equity shares, while the paid-up capital (net of 1,000 forfeited shares from September 1988) is 83,46,75,800 equity shares of Re. 1/- each, aggregating to a total paid-up capital of Rs. 83,46,75,800/-. The company's multi-exchange listing — spanning domestic and international bourses — reflects its stature as a truly global pharmaceutical enterprise.
Strategic Context: ESOPs in Pharma
In the highly competitive global pharmaceutical industry, attracting and retaining scientific talent, regulatory experts, and business leaders is a strategic imperative. ESOPs serve as a critical tool in this context, aligning employee incentives with long-term shareholder value creation. For Dr. Reddy's, which invests significantly in R&D across small molecules, biosimilars, and novel drug delivery systems, retaining core scientific and commercial talent is fundamental to sustaining its innovation pipeline and market competitiveness across regulated markets including the US, Europe, and emerging economies.
Frequently Asked Questions (FAQs)
Q: How many shares did Dr. Reddy's allot on June 19, 2026?
A: Dr. Reddy's allotted 6,730 equity shares of Re. 1/- each on June 19, 2026, under the Employees Stock Option Scheme 2002 and the Employees ADR Stock Option Scheme 2007.
Q: What are the exercise prices for the allotted shares?
A: Three exercise price tranches: 2,455 shares at Re. 1/- each; 2,000 shares at Rs. 562.80/- each; and 2,275 shares at Rs. 735.80/- each.
Q: What is Dr. Reddy's total paid-up equity capital after this allotment?
A: Post-allotment, Dr. Reddy's total paid-up equity capital is 83,46,75,800 equity shares of Re. 1/- each, aggregating to Rs. 83,46,75,800/-.
Q: Are the newly allotted shares subject to any lock-in?
A: No. The allotted shares have no lock-in restrictions and rank pari passu with existing equity shares in all respects, including dividend and voting rights.
Q: Where is Dr. Reddy's Laboratories listed?
A: Dr. Reddy's is listed on BSE (500124), NSE (DRREDDY), NYSE (RDY), and NSE IFSC (DRREDDY). It is headquartered in Hyderabad, Telangana.